MelsDollars Thursday, 07/22/21 12:40:23 PM
Re: Tiger Money post# 41021
Post # 41022 of 41393
The patent includes all derivatives of Aviptadil, which means that any formulation that gets cooked up is still their intellectual property and shared via license with NeuroRX per the agreement.
RLFTF Investor relations was asked about the patent and the profit sharing agreement and they provided this response:
Thank you for your inquiry.
Relief owns U.S. Patent No. 8,178,489, related Patents derived from U.S. Patent Application Serial No. 11/817,867 and foreign formulation patents, which are being utilized under the Collaboration agreement with NeuroRx. Under the collaboration agreement, all potential new IP obtained by either Relief or NeuroRx related to aviptadil is required to be cross-licensed between the parties.
The binding collaboration agreement between Relief Therapeutics and NeuroRx entered into in September 2020 remains in full force and effect. Relief believes that it is in compliance with the collaboration agreement and that there are no grounds for renegotiating the profit sharing arrangements contained in the collaboration agreement. According to the agreement, Relief is entitled to 50% of the net profits from the sales in the NeuroRx territory, which includes the U.S., Canada and Israel.
Regarding questions relating to Relief's funding of the U.S. COVID-19 inhaled trial being conducted by NeuroRx, Relief has always been willing and able to fund the inhaled trial, upon NeuroRx presenting a detailed budget containing appropriate line items and underlying amounts and upon NeuroRx answering reasonable questions that we have posed to them asking for more details about their proposed trial budget. This has not happened to date. Nevertheless, we would also like to point out that Relief has already funded substantial expenses associated with NeuroRx's U.S. inhaled trial.
Kind regards,
Relief Therapeutics
News 
Market Data 
Discover 
